ArticleEuropean radiology2025
Preliminary reports of lung cancer screening with low-dose computed tomography: a nationwide performance on the Korean population in 2019-2020.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundKorea introduced its National Lung Cancer Screening Program (NLCSP) with low-dose computed tomography (LDCT) in 2019. However, there are few published results of lung cancer screening at national level. We investigated the performance of LDCT for lung cancer screening and suggested recommendations for improving a nationwide population-based program. MATERIALS AND
methodsThis study was a nationwide, population-based cross-sectional study. We analyzed the Korean National Health Insurance Big Data Base, which included lung cancer-related screening information between 2019 and 2020, was analyzed. Performance indicators were the number of examinations, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), overexposure, and suspected lung cancer (LCA). The performance indicators were stratified according to screening year, sex, age group, and region.
resultsA total of 149,936 examinations were done in 2019-2020. Most participants were men (98.3%) or were aged 54-59 or 60-64 (35.2% and 38.2%). The sensitivity, specificity, PPV, NPV, overexposure, and suspected LCA were 82.9%, 91.9%, 6.4%, 99.9%, 2.7%, and 4.0%, respectively. Women showed lower sensitivity than men. In 2020, there was a substantial increase in PPV (11.0%), and a substantial decrease in overexposure (47.7%) and suspected LCA (16.9%) compared to 2019. At regional level, there was a large variance in sensitivity, PPV, overexposure, and suspected LCA.
conclusionsKorea's NLCSP successfully demonstrated validity and reliability at national level. Sexual, and regional differences should be addressed to improve NLCSP. KEY POINTS: Question How has biennial low-dose CT (LDCT) lung cancer screening performed in Korea for individuals aged 54-74 years with a smoking history of ≥ 30 pack-years? Findings The sensitivity, specificity, and positive predictive value were 82.9%, 91.9%, and 6.4%. Clinical relevance Korea's program demonstrated a similar level of validity and reliability of previous lung cancer screening studies at national level. It facilitated early diagnosis of lung cancer for all the relevant Korean population and laid the foundation for long-term cancer screening.
Indexed as
Identifiers
40042649What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.